ProPhase Labs PRPH 深 沪
交易中 09-18 11:22:13 美东时间
0.417
-0.005
-1.23%
华盛通- 最 高0.4298
- 今 开0.4228
- 成交量 35.21万股
- 最 低 0.4108
- 昨 收 0.4222
- 总市值 1732.27万
- 52周最高 2.4999
- 市盈率 静 --
- 换手率 0.85%
- 52周最低 0.2179
- 委 比 -34.43%
- 总股本 4154.12万
- 历史最高 15.25
- 量 比 0.66
- 振 幅 4.50%
- 历史最低 -1.87
- 每 手 1
- 风险率 0.70%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多ProPhase Labs Shareholders Approve Strategic Expansion, Including Increase In Authorized Shares To 1B
ProPhase Labs Stockholders Deliver Strong Mandate at Special MeetingUNIONDALE, NY, Sept. 12, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ:PRPH) ("ProPhase" or the "Company"), a next generation biotech, genomics
09-12 20:12
ProPhase Labs Stockholders Approve All Proposals at September 9, 2025 Special Meeting By More Than 75% In Favor
ProPhase Labs shareholders overwhelmingly approved all proposals at the September 9 special meeting, with over 75% support for each item. This included authorization to increase the company's authorized shares to 1 billion, enabling strategic initiatives like a potential crypto treasury strategy and growth of its subsidiaries. The meeting follows the re-election of the board in June with over 90% support. CEO Ted Karkus emphasized the mandate all...
09-12 12:00
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers iSpecimen (NASDAQ:ISPC) shares increased by 80.7% to $1.35 during Tues...
09-10 01:06
ProPhase Labs Inc. to Participate in Renmark’s Virtual Non-Deal Roadshow Series on Thursday, September 4, 2025
ProPhase Labs Inc. will participate in Renmark Financial Communications' virtual non-deal roadshow on September 4, 2025, to discuss its investor presentation, which includes updates on its crypto treasury strategy, potential liquidity events, and the cancellation of the Equity Line of Credit (ELOC). Investors can register for the live event or access the replay post-event via the provided link. The event will feature Ted Karkus, the company's Cha...
09-03 12:00
Prophase Labs Ends Stock Purchase Agreement with Keystone
Prophase Labs ( ($PRPH) ) has issued an update. On August 27, 2025, ProPhase La...
08-28 18:47
ProPhase Labs Q2 EPS $(0.11) Beats $(0.15) Estimate, Sales $1.247M May Not Be Comparable To $3.550M Estimate
The Company did not generate any revenues from diagnostic services for the three months ended June 30, 2025 and 2024, respectively.
08-13 20:04
Earnings Scheduled For August 13, 2025
Companies Reporting Before The Bell • Evotec (NASDAQ:EVO) is projected to repor...
08-13 16:32
Earnings Preview For ProPhase Labs
ProPhase Labs (NASDAQ:PRPH) is set to give its latest quarterly earnings report...
08-13 04:02
ProPhase Labs Announces Full USPTO Approval for Issuance of U.S. Patent Protecting Esophageal Adenocarcinoma Risk Assessment
ProPhase Labs, Inc. has been granted U.S. Patent No. 12379378-B2 for its biomarker-based systems and methods to assess progression risk in Barrett’s esophagus and esophageal adenocarcinoma. This follows the successful validation of its BE-Smart™ molecular diagnostic, achieving over 95% technical success and compatibility with both brush and forceps biopsies, enhancing early detection. The patent, developed by inventors Joe Abdo, Sumeet K. Mittal,...
08-12 12:00
ProPhase Labs Inc. to Present Second Quarter 2025 Financial Results on August 13, 2025
ProPhase Labs Inc. (NASDAQ: PRPH), a biotech and genomics company, will present its second quarter 2025 financial results during a virtual conference call hosted by Renmark Financial on August 13, 2025, at 2:00 pm EDT. Interested stakeholders and investors can register using the provided link. A press release and replay of the event will be available post-call. The company, which specializes in Whole Genome Sequencing, diagnostic development, and...
08-11 12:00
